C2 Therapeutics receives 510(k)

//C2 Therapeutics receives 510(k)

Redwood City, Calif.July 29, 2015 – C2 Therapeutics, a privately held company founded to improve treatment of precursors to esophageal cancer (Barrett’s Esophagus or BE), today announced US Food and Drug Administration (FDA) 510(k) clearance for the Coldplay Cryoballoon™ Full Ablation System and the Coldplay Cryoballoon™ Swipe Ablation System.

“The clearance of Coldplay Cryoballoon Full and Swipe Systems is an important milestone in broadening the company’s portfolio,” said Peter Garcia-Meza, President and CEO of C2 Therapeutics. “The Full and Swipe Ablation Systems will be critical in allowing physicians to ablate larger areas of tissue in endoscopic applications.”

Click here to see full release.

2017-05-16T21:29:57+00:00